Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

03 May 2021 Regulatory

Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning 6 i Göteborg. Inregistrering till...

03 May 2021 Regulatory

Stayble publishes the Annual Report for 2020

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*....

FINANCIAL CALENDAR

Interim report Q1 2021
17May2021
Annual meeting 2021
2June2021
Interim report Q2 2021
16August2021
Interim report Q3 2021
18November2021